Clinical applications of high dose rate endorectal brachytherapy for patients with rectal cancer

T. Vuong, A. Garant, V. Vendrely, A. G. Martin, S. Devic

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


With the establishment of total mesorectal excision for the treatment of rectal cancer, local recurrence rates have significantly decreased. The addition of preoperative external beam irradiation further reduces this risk to less than 6%. As the local treatment becomes successful and more widely used, the associated treatment-related toxicity is becoming clinically important. If 4 to 6% of the patients are to benefit from neo-adjuvant therapy before total mesorectal excision, the acute and the long-term toxicity burden must be reasonable. With the introduction of better-quality imaging for tumour visualization and treatment planning, a new-targeted radiation treatment was introduced with high dose rate endorectal brachytherapy. The treatment concept was tested in phase I and II studies first in the preoperative setting, then as a boost after external beam radiation therapy as a dose escalation study to achieve higher tumour local control in a radical treatment setting with no surgery. High dose rate endorectal brachytherapy is safe and effective in achieving high tumour regression rate and was well tolerated. It is presently explored in a phase III dose escalation study in the non-operative management of patients with operable rectal cancer.

Original languageEnglish (US)
Pages (from-to)879-883
Number of pages5
Issue number6-7
StatePublished - Oct 2022


  • Non-operative management of rectal cancer
  • Rectal brachytherapy
  • Targeted therapy for rectal cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Clinical applications of high dose rate endorectal brachytherapy for patients with rectal cancer'. Together they form a unique fingerprint.

Cite this